Li X, Fang Q, Du W, et al. - Whether sintilimab combined with induction chemotherapy (IC) affords an efficacious and safe treatment strategy for locally advanced head and neck squamous cell carcinoma, was investigated herein. This study included 163 patients; 98 underwent IC only, and 65 underwent IC with sintilimab. Post-neoadjuvant therapy, patients either received surgery (31.9%) or chemoradiotherapy (68.1%). Significantly lower objective response rate was obtained in the IC group vs that in the IC with sintilimab group. Longer progression free survival time without increasing the toxicity events could be conferred by addition of sintilimab to IC vs traditional chemotherapy regimen.